Diabetic Nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Intervention 1: For patients in the first intervention group, 10 mg of Empagliflozin (manufactured by Dr. Abidi Pharmaceutical Company under the brand name Gloripa) is administered orally once daily f
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age over 30 years and under 75 years Type 2 diabetes The patient has microalbuminuria
Exclusion criteria
Exclusion criteria: HbA1C>9% uncontrolled blood pressure uncontrolled blood sugar heart failure chronic liver disease GFR<30 presence of hematuria signs of active urinary and renal infection uinary catheter High stages of nephropathy other kidney diseases that cause albuminuria such as glomerulonephritis acute hospital conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of mean albuminuria between the group receiving Empagliflozin with the group receiving Linagliptin at the beginning and end of the study. Timepoint: At the beginning of the study and ninety days after starting the drug. Method of measurement: Measurement of urinary microalbumin exceretion sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Amin Mohammadzadeh Gharabaghi
Arak University of Medical Sciences
Outcome results
None listed